DBC1によってSIRT1脱酸化酵素の負の調節
Wenhui Zhao1, Jan-Philipp Kruse, Yi Tang
1Institute for Cancer Genetics, and Department of Pathology College of Physicians and Surgeons, Columbia University, 1130 St Nicholas Avenue, New York, New York 10032, USA.
Nature
|February 1, 2008
まとめ
Deleted in breast cancer 1 (DBC1) は,SIRT1のデセチラゼ活性を抑制する. DBC1の減少はSIRT1を強化する.
科学分野:
- 分子生物学は分子生物学である.
- 細胞生物学 細胞生物学
- バイオケミストリー バイオケミストリー
背景:
- SIRT1はNAD依存型脱酸化酵素であり,ストレス反応,代謝,老化を調節する.
- SIRT1は腫瘍抑制剤p53を脱酸化し,細胞生存を促進する.
- SIRT1の活性 in vivo の調節は,まだ十分に理解されていない.
研究 の 目的:
- SIRT1活動のインビボ調節を調査する.
- SIRT1.1のネイティブ阻害剤を特定する.
- SIRT1媒介によるp53調節におけるDBC1の役割を明らかにする.
主な方法:
- DBC1減退のためのRNA干渉 (RNAi).
- p53アセチル化とアポトーシスの分析.
- SIRT1の活性検査.SIRT1の活性検査.
主要な成果:
- DBC1は,ヒト細胞におけるSIRT1のネイティブ阻害剤として作用する.
- DBC1媒介によるSIRT1抑制により,p53のアセチル化と機能が増加する.
- DBC1の減少はSIRT1の活動を刺激し,p53の脱酸化とアポトーシスの抑制につながります.
結論:
- DBC1は,特にSIRT1のデセチラゼ活性を抑制する.
- DBC1は,SIRT1.1.を阻害することによって,p53-媒介によるアポトーシスを促進する.
- DBC1は,アポトーシスなどの細胞プロセスにおけるSIRT1機能の重要な調節体です.
関連する概念動画
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Spreading of Chromatin Modifications
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer is an enzyme that can...
Writers
The writer is an enzyme that can...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...


